(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual revenue growth rate of 10.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Biomarin Pharmaceutical's revenue in 2025 is $2,853,915,000.On average, 11 Wall Street analysts forecast BMRN's revenue for 2025 to be $597,671,117,932, with the lowest BMRN revenue forecast at $591,618,715,957, and the highest BMRN revenue forecast at $608,483,407,354. On average, 11 Wall Street analysts forecast BMRN's revenue for 2026 to be $654,315,113,995, with the lowest BMRN revenue forecast at $607,739,376,851, and the highest BMRN revenue forecast at $706,760,297,921.
In 2027, BMRN is forecast to generate $730,121,901,824 in revenue, with the lowest revenue forecast at $688,815,808,410 and the highest revenue forecast at $767,076,370,682.